321 related articles for article (PubMed ID: 29847773)
1. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Tusskorn O; Kukongviriyapan V
Life Sci; 2018 Aug; 207():172-183. PubMed ID: 29847773
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Kukongviriyapan V
Life Sci; 2019 Jan; 217():155-163. PubMed ID: 30528773
[TBL] [Abstract][Full Text] [Related]
3. Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways.
Wandee J; Srinontong P; Prawan A; Senggunprai L; Kongpetch S; Yenjai C; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1929-1940. PubMed ID: 34086099
[TBL] [Abstract][Full Text] [Related]
4. Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways.
Jaidee R; Kongpetch S; Senggunprai L; Prawan A; Kukongviriyapan U; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1681-1690. PubMed ID: 32383028
[TBL] [Abstract][Full Text] [Related]
5. Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Saengboonmee C; Seubwai W; Cha'on U; Sawanyawisuth K; Wongkham S; Wongkham C
Anticancer Res; 2017 Jan; 37(1):115-123. PubMed ID: 28011481
[TBL] [Abstract][Full Text] [Related]
6. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
7. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents.
Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan U; Kukongviriyapan V
Tumour Biol; 2016 Aug; 37(8):11495-507. PubMed ID: 27015836
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells.
Tusskorn O; Khunluck T; Prawan A; Senggunprai L; Kukongviriyapan V
Biomed Pharmacother; 2019 Mar; 111():109-118. PubMed ID: 30579250
[TBL] [Abstract][Full Text] [Related]
12. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
13. AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.
Su CC; Hsieh KL; Liu PL; Yeh HC; Huang SP; Fang SH; Cheng WC; Huang KH; Chiu FY; Lin IL; Huang MY; Li CY
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987073
[TBL] [Abstract][Full Text] [Related]
14. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
15. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
16. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
17. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
[TBL] [Abstract][Full Text] [Related]
18. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R
J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220
[TBL] [Abstract][Full Text] [Related]
19. Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms.
Xiong ZS; Gong SF; Si W; Jiang T; Li QL; Wang TJ; Wang WJ; Wu RY; Jiang K
Mol Med Rep; 2019 Aug; 20(2):887-894. PubMed ID: 31173255
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
